Drug Trial Radar · NCT06193200
Evaluate the Neurological Effects of EryDex on Subjects With A-T
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jun 24, 2024
Primary completion
Dec 17, 2025
Study completion Dec 17, 2025
Sponsor
- Lead sponsor
- Quince Therapeutics S.p.A.Industry
- Sponsor type
- Industry
- Collaborators
- Biotrial
- First posted
- Jan 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).
Conditions
- Ataxia Telangiectasia
Interventions
Dexamethasone sodium phosphateDrug
Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion
PlaceboOther
Placebo encapsulated in autologous erythrocytes and administered via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS)Time frame: Baseline to Visit 9 (approximately 6 months)
Locations
19 sites in 9 countries. Site status is shown where the registry gives one.
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence
Los Angeles, California
The Johns Hopkins Hospital, Division of pediatric allergy and immunology
Baltimore, Maryland
Cincinnati Children's Hospital, Division of neurology
Cincinnati, Ohio
UT Health Houston, Department of pediatrics, division of child & adolescent neurology
Houston, Texas
Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology
Copenhagen, Denmark
University Hospital Frankfurt, Pediatric and Adolescent Clinic
Frankfurt, Germany
IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases
Frankfurt, Germany
Spedali Civili di Brescia, Pediatric immunology department
Brescia, Italy
Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health
Roma, Italy
Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening
Oslo, Norway
MedPolonia sp zoo
Poznan, Poland
Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic
Warsaw, Poland
Hospital Universitari Vall d'Hebron, Department of pediatric neurology
Barcelona, Spain
Hospital Universitario La Paz, Department of pediatric neurology
Madrid, Spain
University Children's Hospital Zürich - Eleonore Foundation
Zurich, Switzerland
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
St George's University Hospitals NHS Foundation Trust, Centre for Neonatal and Paediatric Infection
London, United Kingdom
Great Ormond Street Hospital for Children, Zayed Centre for Research
London, United Kingdom
Nottingham Children's Hospital, Queen's Medical Center, Children's neurology
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.